Recommendation of the President – Keytruda (pembrolizumab)
On 2 June 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 67/2025 on the appraisal of drug Keytruda (pembrolizumab) as part of Drug Program B.159: “Treatment of Patients with Cervical Cancer (ICD-10: C53)”